• Explore /
  • Poster
  • / OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

Abstract Video & Slides Poster

Authors

null

Jean-Luc Van Laethem

Erasme University Hospital, Brussels, Belgium

Jean-Luc Van Laethem , Ivan Borbath , Karen Paula Geboes , Philippe Alexandre Cassier , Aurélien Lambert , Emmanuel Mitry , Hans Prenen , Lorenzo Pilla , Jean-Frédéric Blanc , Inmaculada Gallego Jiménez , Roberto A. Pazo Cid , Mercedes Rodríguez Garrote , Jaime Feliú , Karin Nordbladh , Karin Enell Smith , David Gomez Jimenez , Peter Ellmark , Yago Pico de Coaña , Sumeet Vijay Ambarkhane , Teresa Macarulla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04888312

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4133)

DOI

10.1200/JCO.2024.42.16_suppl.4133

Abstract #

4133

Poster Bd #

113

Abstract Disclosures

Similar Posters

First Author: Hiroyuki Asama

First Author: Luis G. Paz-Ares

First Author: Shun Tezuka

First Author: Takenori Takahata